Amplia Therapeutics Puts Trial Recruitment on Hold; Shares Dive 25%
MT Newswires Live
Apr 07
Amplia Therapeutics (ASX:ATX) stopped further recruitment in the Amplicity clinical trial following three dose-limiting toxicities, according to a Tuesday filing with the Australian bourse.
The trial is investigating the company's lead drug narmafotinib in combination with the chemotherapy regimen modified Folfirinox in advanced pancreatic cancer, the filing said.
Among the eight patients, three events of protocol-defined dose-limiting toxicities have been observed relating to the chemotherapy regimen.
The remaining five patients will remain on study and continue to receive the combination with continued safety monitoring, per the filing.
The company's shares tumbled 25% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.